tirzepatide osa approval (Zepbound) – A New Treatment for Obstructive Sleep Apnea and Obesity — BetterNight FDA approves Zepbound for obstructive

Ozempic is approved at up to 2 mg/week and is indicated for type 2 diabetes (though providers may prescribe it off-label for weight loss)

The content of this workshop is not meant to replace therapy and is not considered mental health treatment

Adults over the age of 65 Due to a number of common issues associated with ageing, including the reduced production of stomach acid, people over the age of 65 may be more prone to a B12 deficiency

This refers to the specific modifications made to the standard IGF-1 moleculean Arginine replacing a Glutamic Acid at the 3rd position and a 13 amino acid extensionto extend its half-life

GLP 1s are best understood as one tool in a broader treatment plan rather than a standalone solution